Compare HQH & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HQH | CADL |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | HQH | CADL |
|---|---|---|
| Price | $21.80 | $10.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 179.1K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ 1.09 | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.36 | $4.35 |
| 52 Week High | $24.85 | $14.00 |
| Indicator | HQH | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 36.02 | 42.84 |
| Support Level | $18.72 | $4.91 |
| Resistance Level | $22.29 | $11.36 |
| Average True Range (ATR) | 0.39 | 0.69 |
| MACD | -0.23 | -0.26 |
| Stochastic Oscillator | 0.19 | 5.54 |
abrdn Healthcare Investors Formerly Tekla Healthcare Investors is the United States based non-diversified closed-end management investment company. Its objective is to seek long-term capital appreciation by investing in securities of healthcare companies. In addition, the fund seeks to provide regular distribution of realized capital gains. The fund invests in the securities of public and private companies.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.